Abstract Mitochondrial dysfunction is observed in brains of Alzheimer's Disease patients as well as many rodent model systems including those modeling mutations in preseinilin 1 (PSEN1). The aim of our study was to characterize mitochondrial function and number in fibroblasts from AD patients with PSEN1 mutations. We used biochemical assays, metabolic profiling and fluorescent labeling to assess mitochondrial number and function in fibroblasts from three AD patients compared to fibroblasts from three controls. The mutant AD fibroblasts had increased Aβ42 relative to controls along with reduction in ATP, basal and maximal mitochondrial respiration as well as impaired spare mitochondrial respiratory capacity. Fluorescent staining and expression of genes encoding electron transport chain enzymes showed diminished mitochondrial content in the AD fibroblasts. This study demonstrates that mitochondrial dysfunction is observable in AD fibroblasts and provides evidence that this model system could be useful as a tool to screen disease-modifying compounds.
Introduction
While genetic forms of Alzheimer's disease (AD) do not account for the majority of cases, there are several known mutations that result in the disease. Mutations in presenilin-1(PSEN1) result in the most prevalent form of inherited AD (Bekris et al. 2010 , Elder et al. 2010 . PSEN1 is a key component of the y-secretase complex which mediates one of the cleavage events that converts amyloid precursor protein into Aβ. Mutations in PSEN1 increase the production of Aβ42 which is more likely to oligomerize and accumulate. This accumulation of Aβ is associated with mitochondrial dysfunction and cognitive impairment (Du et al. 2010 , Rhein et al. 2009b , Yao et al. 2009 ). In vitro studies likewise suggest a relationship between Aβ accumulation and mitochondrial function (Hensley et al. 1994 , Rhein et al. 2009a . The hypothesis that mitochondrial dysfunction contributes to cognitive decline has led to a growing interest in identifying therapies that target mitochondrial function as a treatment for AD. Yet physiologically relevant model systems to test such treatments remain limited.
The aim of this was to characterize mitochondrial function in human fibroblasts to determine whether abnormalities are observable in a defined population of AD patients. A variety of biochemical techniques were used to compare mitochondrial number and content of fibroblasts from AD patients with mutations in PSEN1 to control fibroblasts.
Methods

Cell culture fibroblasts
Fibroblasts were obtained from 3 AD patient with PSEN1 mutations, and three healthy controls (NINDS repositoryCorriell) and cultured in growth media containing MEMα (Gibco) with 10 %FBS and 1 % penicillin-streptomycin (Sigma-Aldrich).
ATP quantification
ATP was quantified using ATP determination kit (Invitrogen) as per the manufacturer's instructions and normalized to protein content determined by bicinchoninic acid (BCA).
Analysis of mitochondrial function
Mitochondrial function was assessed using the Seahorse Bioscience XF24 Extracellular Flux Analyzer. Fibroblasts were plated in growth medium at a density of in 150,000 cells/well, which was determined to be optimal for basal O 2 consumption rate (OCR). The following day cells were rinsed in assay medium (pH 7.4) containing XF Base medium (Seahorse Bioscience), 5.5 mM glucose and 1 mM sodiumpyruvate. Cells remained in assay medium 1 h at 37°C in a non-CO2 incubator prior to initializing the Seahorse24XF analysis. Using the MitoStress Kit as previously described (Wu et al. 2007 ), OCR was measured under basal conditions as well as after sequential treatment with the ATP synthase inhibitor oligomycin (1 μm), an electron transport chain (ETC) accelerator, p-trifluoromethoxy carbonyl cyanide phenyl hydrazone (FCCP at 1.5 μm and the mitochondrial inhibitors rotenone (1 μm) and antimycin (1 μm). Three measurements were taken under each condition. The respiration following antimycin and rotenone treatment was used to correct for non-mitochondrial oxygen consumption. Data was normalized to total DNA content, which was determined from each well using the CyQuant kit (Invitrogen) as per the manufacturer's instructions.
Quantitative real time PCR
Cells were harvested and RNA was extracted using TriReagent (Molecular Research Center). RNA was reverse transcribed with the Superscript III First Strand Synthesis kit (Invitrogen) as per the manufacturer's instructions. Relative gene expression was determined using TaqMan Gene Expression Master Mix (Invitrogen) and commercially available TaqMan primers (Invitrogen) for mitochondrially encoded NADH dehydrogenase 1 (Mt-ND1), mitochondrially encoded ATP synthase 6 (Mt-ATP6), mitochondrially encoded cytochrome c oxidase 1 (Mt-CO1), mitochondrially encoded cytochrome B (Mt-CYB) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Quantitative PCR (qPCR) was performed on a StepOne Plus Machine (Applied Biosystems) and analyzed using the delta-delta Ct method.
Mitochondrial number
Relative mitochondrial number was determined using MitoTracker Green dye (Invitrogen) as per the manufacturer's instructions. Briefly cells were incubated with 100 nM dye for 25 min, rinsed in fresh media and fluorescence was quantified using a Victor 3 fluorescent plate reader (Perkin Elmer).
Statistics
Statistical significance was determined using t-tests. Bonferroni post-hoc tests were also conducted. Significance was defined as p≤0.05. Analyses were performed using Excel or GraphPad Prism 6.
Results
Mitochondrial function is impaired in AD fibroblasts
ATP levels were significantly reduced in AD fibroblasts (Fig. 1a) . The metabolic profile of mitochondrial function revealed concordant deficiencies in cellular and mitochondrial oxygen consumption in the AD fibroblasts (Fig. 1b) . After adjusting for non-mitochondrial respiration both basal and maximal respiration were decreased in AD fibroblasts as was spare capacity (Fig. 1c) .
Mitochondrial content is decreased in AD fibroblasts
Decreased mitochondrial number was also observed in AD fibroblasts as evidenced by reduced MitoTracker fluorescence (Fig. 2a) . Consistent with this finding, decreased expression of several electron transport chain (ETC.) genes was also seen in AD fibroblasts relative to controls (Fig. 2b) . Expression of genes encoding enzymes in complexes I, III, IV and V were all reduced by approximately 50 % in AD fibroblasts.
Discussion
Neuronal mitochondrial dysfunction is an early and prominent feature of AD (Wang et al. 2009 ) as is reduced energy metabolism in the brain (Landau et al. 2011 , Shokouhi et al. 2013 , Yamane et al. 2013 ). Diminished neuronal expression of genes encoding subunits of the ETC, as well as decreased expression or activity of many enzymes involved in oxidative metabolism, are also well-documented in AD brains (Cottrell et al. 2001 , Gibson et al. 1998 , Nagy et al. 1999 , Parker et al. 1994 . Calcium dyshomeostasis, altered glucose metabolism, and increased oxidative stress have all also been observed in peripheral tissue including fibroblasts (Peterson and Goldman 1986 , Sims et al. 1987 , Torres et al. 2011 . In this study we have demonstrated that in a genetically defined population of AD patients, alterations in mitochondrial number and bioenergetic profile are indeed observable outside of the brain.
Fibroblasts from AD patients with PSEN1 mutations were shown to have decreased ATP content and significant impairments in mitochondrial respiration. Decreased basal and maximal respiration, as well as diminished spare capacity were observed in these AD fibroblasts. Consistent with the decrease in basal respiration, genes encoding enzymes in the ETC were also found to be coordinately down-regulated in AD fibroblasts indicative of a reduction in mitochondrial number which was similarly observed using fluorescent mitochondrial labeling. Mitochondrial gene expression was decreased by approximately 50 % in the AD fibroblasts while the fluorescent labeling showed a decrease of only about 25 % in those fibroblasts. This discrepancy is like the due to differences in sensitivity of the assays, as qPCR is a far more sensitive technique than quantifying fluorescence.
The findings from this study are in line with previous reports of mitochondrial changes in the brain of AD patients as well as in animal models of AD. Altered brain mitochondrial function can be detected by NMR in AD mice (Lalande et al. 2014 , Lin et al. 2014 ) as well as human AD patients (Targosz-Gajniak et al. 2013 , Zhong et al. 2014 , Fayed et al. 2011 . The cause of this mitochondrial dysfunction has yet to be elucidated, although increased Aβ accumulation has been implicated. Aβ treatment of cultured neuronal-derived cells results in ROS generation, decreased ATP production, and disrupted mitochondrial membrane potential (Hensley et al. 1994 , Rhein et al. 2009a ) and synaptic Aβ accumulation in primary neurons leads to mitochondrial dysfunction and synaptic degradation (Du et al. 2010) . As has been previously reported (Johnston et al. 1994 , Sproul et al. 2014 we also observed greater AB42 accumulation in the AD fibroblasts as compared to controls (data not shown). Yet the extent to which this Aβ accumulation contributes to the mitochondrial abnormalities observed in AD fibroblasts remains to be seen. The consistent association between mitochondrial dysfunction and AD has led to the hypothesis that these mitochondrial changes precede and may contribute to the cognitive decline in AD (Leuner et al. 2012 , Swerdlow 2007 . The fact that these changes are also observable in fibroblasts suggests potential utility of this model system as a physiologically relevant and more accessible method to screen for diseasemodifying compounds. Future experiments are needed with fibroblasts isolated from idiopathic AD to validate this system beyond genetic AD patients.
